Molecular Partners AG Share Price & Technical Analysis
MOLN · $4.18 (+10.00%)
Healthcare / Biotechnology
$4.18
+10.00%
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treat…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-7% return in May, 0% avg return in past 3 year May month.
-19% return in 2026, 0% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -5% | 9% | -22% | 5% | -7% | – | – | – | – | – | – | – | -19% |
| 25 | 4% | -2% | -22% | -5% | 6% | 6% | 0% | 12% | -5% | -3% | 3% | 5% | -3% |
| 24 | 30% | -10% | -5% | -10% | -5% | 71% | 16% | -30% | -11% | 13% | -6% | -19% | 34% |
| 23 | 0% | -3% | -2% | 14% | -2% | -2% | -2% | 0% | -31% | -15% | 14% | -2% | -30% |
| 22 | 37% | -15% | -18% | -60% | -3% | -9% | -9% | -5% | 20% | -9% | 0% | -7% | -77% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$151.15M
P/E ratio
—
52W high
$5.36
52W low
$3.41
Volume
10,742
Beta
0.74
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Molecular Partners AG share price today?
- Molecular Partners AG (MOLN) last traded around $4.18 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MOLN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MOLN. Download the app for real-time alerts.
- How can I analyze Molecular Partners AG stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.